Log in
NASDAQ:DMAC

DiaMedica Therapeutics Stock Forecast, Price & News

$4.38
-0.03 (-0.68 %)
(As of 09/18/2020 09:21 PM ET)
Add
Compare
Today's Range
$4.31
Now: $4.38
$4.60
50-Day Range
$4.07
MA: $4.94
$6.12
52-Week Range
$1.70
Now: $4.38
$8.80
Volume48,300 shs
Average Volume60,843 shs
Market Capitalization$82.08 million
P/E RatioN/A
Dividend YieldN/A
Beta2.43
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMAC
CUSIPN/A
CIKN/A
Phone763-312-6755

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$0.64 per share

Profitability

Net Income$-10,650,000.00

Miscellaneous

Employees9
Market Cap$82.08 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$4.38
-0.03 (-0.68 %)
(As of 09/18/2020 09:21 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

How has DiaMedica Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DMAC stock has increased by 9.5% and is now trading at $4.38.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of DiaMedica Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for DiaMedica Therapeutics
.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for DiaMedica Therapeutics
.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc (NASDAQ:DMAC) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.02.
View DiaMedica Therapeutics' earnings history
.

What price target have analysts set for DMAC?

3 analysts have issued 1-year target prices for DiaMedica Therapeutics' shares. Their forecasts range from $14.00 to $15.00. On average, they expect DiaMedica Therapeutics' share price to reach $14.33 in the next twelve months. This suggests a possible upside of 227.2% from the stock's current price.
View analysts' price targets for DiaMedica Therapeutics
.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 26,100 shares, an increase of 12.5% from the August 15th total of 23,200 shares. Based on an average trading volume of 71,200 shares, the days-to-cover ratio is presently 0.4 days.
View DiaMedica Therapeutics' Short Interest
.

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), Oncolytics Biotech (ONCY), Pfizer (PFE), AbbVie (ABBV), Adamis Pharmaceuticals (ADMP) and Amarin (AMRN).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 57)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

Who are DiaMedica Therapeutics' major shareholders?

DiaMedica Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Corriente Advisors LLC (1.42%) and Bank of New York Mellon Corp (0.10%). Company insiders that own DiaMedica Therapeutics stock include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends for DiaMedica Therapeutics
.

Which institutional investors are buying DiaMedica Therapeutics stock?

DMAC stock was purchased by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, and Bank of New York Mellon Corp. Company insiders that have bought DiaMedica Therapeutics stock in the last two years include Dietrich John Pauls, Harry W Alcorn Jr, Randall Michael Giuffre, Richard D Pilnik, and Scott Kellen.
View insider buying and selling activity for DiaMedica Therapeutics
.

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $4.38.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $82.08 million and generates $500,000.00 in revenue each year. The company earns $-10,650,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.